Mifepristone | Korlym (Corcept Therapeutics, Inc.) | Korlym is approved for use in patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not responded to prior surgery. | Drug Information Portal
|
Pasireotide | Signifor (Novartis Pharmaceuticals Corporation) | Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative | Drug Information Portal
|